Skip to main content

Table 2 Circulating concentrations of OPG and risk of death following a breast cancer diagnosis, by ER subtype

From: Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort

Cut points (pmol/L)

Quintiles

ptrenda

HRlog2

phetb

1

2

3

4

5

≤ 7.80

7.80–9.18

9.18–10.54

10.54–12.38

>  12.38

Breast cancer-specific death

All breast cancer cases

  Died/total

51/402

48/401

44/401

55/401

52/401

 

250/2006

 

  HR (95% CI)

Ref.

1.04 (0.70, 1.57)

0.96 (0.63, 1.48)

1.33 (0.88, 2.00)

1.37 (0.90, 2.09)

0.13

1.30 (0.93, 1.80)

0.58

  sRANKL adjusted

  HR (95% CI)c

Ref.

1.08 (0.72, 1.63)

1.02 (0.66, 1.57)

1.32 (0.86, 2.01)

1.45 (0.93, 2.27)

0.12

1.32 (0.93, 1.88)

0.55

ER+ breast cancer cases

  Died/total

31/318

35/321

27/322

35/328

37/331

 

165/1620

 

  HR (95% CI)

Ref.

1.34 (0.81, 2.20)

1.08 (0.62, 1.85)

1.47 (0.88, 2.46)

1.77 (1.03, 3.04)

0.10

1.43 (0.94, 2.17)

 

  sRANKL adjusted

  HR (95% CI)c

Ref.

1.44 (0.87, 2.39)

1.17 (0.67, 2.03)

1.52 (0.89, 2.59)

2.02 (1.15, 3.54)

0.07

1.52 (0.97, 2.36)

 

ER- breast cancer cases

  Died/total

20/84

13/80

17/79

20/73

15/70

 

85/386

 

  HR (95% CI)

Ref.

0.71 (0.34, 1.51)

0.77 (0.38, 1.57)

1.27 (0.63, 2.54)

0.91 (0.44, 1.89)

0.60

1.16 (0.68, 1.99)

 

  sRANKL adjusted

  HR (95% CI)c

Ref.

0.70 (0.32, 1.52)

0.80 (0.38, 1.68)

1.20 (0.58, 2.52)

0.86 (0.38, 1.93)

0.72

1.12 (0.62, 2.02)

 

Death of any cause

All breast cancer cases

  Alive/ total

77/402

71/401

71/401

93/401

109/401

 

421/2006

 

  HR (95% CI)

Ref.

0.88 (0.64, 1.23)

0.83 (0.59, 1.17)

1.10 (0.80, 1.52)

1.25 (0.90, 1.73)

0.02

1.37 (1.05, 1.78)

0.66

  sRANKL adjusted

  HR (95% CI)c

Ref.

0.90 (0.65, 1.26)

0.83 (0.59, 1.17)

1.04 (0.75, 1.45)

1.20 (0.85, 1.69)

0.07

1.29 (0.98, 1.70)

0.66

ER+ breast cancer cases

  

  Died/total

53/318

54/321

47/322

71/328

84/330

 

310/1620

 

  HR (95% CI)

Ref.

1.00 (0.68, 1.48)

0.83 (0.55, 1.26)

1.20 (0.82, 1.75)

1.39 (0.94, 2.05)

0.02

1.44 (1.06, 1.96)

 

  sRANKL adjusted

  HR (95% CI)c

Ref.

1.04 (0.70, 1.54)

0.85 (0.56, 1.29)

1.17 (0.79, 1.72)

1.38 (0.92, 2.08)

0.05

1.39 (1.00, 1.92)

 

ER- breast cancer cases

  Died/total

24/84

17/80

24/79

22/73

24/70

 

111/386

 

  HR (95% CI)

Ref.

0.70 (0.36, 1.35)

0.80 (0.43, 1.49)

1.02 (0.54, 1.93)

1.04 (0.55, 1.94)

0.34

1.27 (0.78, 2.08)

 

  sRANKL adjusted

  HR (95% CI)c

Ref.

0.68 (0.34, 1.35)

0.74 (0.38, 1.42)

0.90 (0.46, 1.75)

0.86 (0.43, 1.32)

0.75

1.09 (0.63, 1.89)

 
  1. All models adjusted for breast cancer stage (localized, non-localized, missing), BMI (kg/m2), age at blood collection (years), and age groups at menarche (≤11, 12, 13 and missing, 14, ≥15 years), menopause (premenopausal ≤ 48, 49–51, ≥52 years, missing), and first full term pregnancy (nulliparous, < 25 years, ≥25 years and missing); stratifying by age groups at diagnosis (5 year groups) and models in all cases by ER status of the tumor
  2. aptrend based on log2-transformed OPG concentrations; b pheterogeneity comparing model without to model with interaction term for OPG and ER status using log likelihood ratio tests; c additionally adjusting for sRANKL concentrations (42 observations missing sRANKL concentrations; analyses include 245 breast cancer deaths, 412 deaths of any cause)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us